Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant - Hsu, P.-Y., Wu, V. S., Kanaya, N., Petrossian, K., Hsu, H.-K., Nguyen, D., Schmolze, D., Kai, M., Liu, C.-Y., Lu, H., Chu, P., Vito, C. A., Kruper, L., Mortimer, J., Chen, S. (The American Association for Cancer Research (AACR), 2018)
6139904